Cargando…

Medical management of primary hyperparathyroidism

Primary hyperparathyroidism (PHPT) is an endocrine disorder resulting from the hyperfunction of one or more parathyroid glands, with hypersecretion of parathyroid hormone (PTH). It can be managed by parathyroidectomy (PTX) or non-surgically. Medical therapy with pharmacological agents is an alternat...

Descripción completa

Detalles Bibliográficos
Autores principales: Bandeira, Francisco, Nóbrega, Janiere de Moura, de Oliveira, Lucian Batista, Bilezikian, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Endocrinologia e Metabologia 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118813/
https://www.ncbi.nlm.nih.gov/pubmed/36382758
http://dx.doi.org/10.20945/2359-3997000000558
_version_ 1785028881585012736
author Bandeira, Francisco
Nóbrega, Janiere de Moura
de Oliveira, Lucian Batista
Bilezikian, John
author_facet Bandeira, Francisco
Nóbrega, Janiere de Moura
de Oliveira, Lucian Batista
Bilezikian, John
author_sort Bandeira, Francisco
collection PubMed
description Primary hyperparathyroidism (PHPT) is an endocrine disorder resulting from the hyperfunction of one or more parathyroid glands, with hypersecretion of parathyroid hormone (PTH). It can be managed by parathyroidectomy (PTX) or non-surgically. Medical therapy with pharmacological agents is an alternative for those patients with asymptomatic PHPT who meet guidelines for surgery but are unable or unwilling to undergo PTX. In this review, we focus upon these non-surgical aspects of PHPT management. We emphasize the most studied and widely used pharmacological alternatives: bisphosphonates, denosumab, cinacalcet and hormone therapy, in addition to combined therapy. We also address the relevant aspects of perioperative management.
format Online
Article
Text
id pubmed-10118813
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Sociedade Brasileira de Endocrinologia e Metabologia
record_format MEDLINE/PubMed
spelling pubmed-101188132023-04-21 Medical management of primary hyperparathyroidism Bandeira, Francisco Nóbrega, Janiere de Moura de Oliveira, Lucian Batista Bilezikian, John Arch Endocrinol Metab Review Primary hyperparathyroidism (PHPT) is an endocrine disorder resulting from the hyperfunction of one or more parathyroid glands, with hypersecretion of parathyroid hormone (PTH). It can be managed by parathyroidectomy (PTX) or non-surgically. Medical therapy with pharmacological agents is an alternative for those patients with asymptomatic PHPT who meet guidelines for surgery but are unable or unwilling to undergo PTX. In this review, we focus upon these non-surgical aspects of PHPT management. We emphasize the most studied and widely used pharmacological alternatives: bisphosphonates, denosumab, cinacalcet and hormone therapy, in addition to combined therapy. We also address the relevant aspects of perioperative management. Sociedade Brasileira de Endocrinologia e Metabologia 2022-11-10 /pmc/articles/PMC10118813/ /pubmed/36382758 http://dx.doi.org/10.20945/2359-3997000000558 Text en https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Bandeira, Francisco
Nóbrega, Janiere de Moura
de Oliveira, Lucian Batista
Bilezikian, John
Medical management of primary hyperparathyroidism
title Medical management of primary hyperparathyroidism
title_full Medical management of primary hyperparathyroidism
title_fullStr Medical management of primary hyperparathyroidism
title_full_unstemmed Medical management of primary hyperparathyroidism
title_short Medical management of primary hyperparathyroidism
title_sort medical management of primary hyperparathyroidism
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118813/
https://www.ncbi.nlm.nih.gov/pubmed/36382758
http://dx.doi.org/10.20945/2359-3997000000558
work_keys_str_mv AT bandeirafrancisco medicalmanagementofprimaryhyperparathyroidism
AT nobregajanieredemoura medicalmanagementofprimaryhyperparathyroidism
AT deoliveiralucianbatista medicalmanagementofprimaryhyperparathyroidism
AT bilezikianjohn medicalmanagementofprimaryhyperparathyroidism